Glenmark Pharma Fact Sheet, Glenmark Pharma Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glenmark Pharma Fact Sheet    (GLPH)


India's Revival: A Once-in-a-Generation Wealth Making Opportunity


Here is the latest financial fact sheet of Glenmark Pharma. For more details, see the Glenmark Pharma quarterly results and Glenmark Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

GLENMARK PHARMA Price History

Price Rs 503.4
Mkt Cap Rs m 142,029
Vol '000 226.5
P/E X 15.4
P/CF X 11.4
EPS (TTM) Rs 32.6
% ch % 1.0
No. of shares m 282.17
% ch week % 5.1
% ch 1-mth % 6.0
% ch 12-mth % 103.2
52 week H/L Rs 572.7/253.0
(As on Apr 13, 2021 01:03:00 PM)
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

GLENMARK PHARMA Financials

No. of Mths
Year Ending
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
12
Mar-18
*
12
Mar-19
*
5-Yr Chart
Click to enlarge
GLENMARK PHARMA EQUITY SHARE DATA
High Rs8791,262993930712 
Low Rs752672729517484 
Sales per share (Unadj.) Rs244.4271.1325.5322.6349.6 
Earnings per share (Unadj.) Rs17.526.339.328.532.8 
Diluted earnings per shareRs16.826.339.328.532.8 
Cash flow per share (Unadj.) Rs27.134.648.739.244.3 
Dividends per share (Unadj.) Rs2.002.002.002.002.00 
Adj. dividends per shareRs1.922.002.002.002.00 
Dividend yield (eoy) %0.20.20.20.30.3 
Book value per share (Unadj.) Rs86.1128.6159.2183.0198.6 
Adj. book value per shareRs82.8128.6159.2183.0198.6 
Shares outstanding (eoy) m271.29282.16282.17282.17282.17 
Bonus/Rights/Conversions  --ESOP-- 
Price / Sales ratio x3.33.62.62.21.7 
Avg P/E ratio x46.636.721.925.418.2 
P/CF ratio (eoy) x30.127.917.718.513.5 
Price / Book Value ratio x9.57.55.44.03.0 
Dividend payout %11.47.65.17.06.1 
Avg Mkt Cap Rs m221,284272,778242,991204,206168,625 
No. of employees `0009.510.013.013.712.0 
Total wages/salary Rs m12,02413,78216,40818,71820,561 
Avg. sales/employee Rs Th6,961.17,630.57,083.96,636.88,196.0 
Avg. wages/employee Rs Th1,262.51,374.81,265.41,364.71,708.1 
Avg. net profit/employee Rs Th499.0741.2855.1586.1768.5 
GLENMARK PHARMA INCOME DATA
Net Sales Rs m66,29876,49691,85791,03198,655 
Other income Rs m2192003749142,081 
Total revenues Rs m66,51676,69692,23091,945100,736 
Gross profit Rs m10,22514,37220,36716,15415,858 
Depreciation Rs m2,6002,3432,6443,0193,259 
Interest Rs m1,9021,7892,3732,8563,346 
Profit before tax Rs m5,94310,44015,72411,19311,335 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m00-81001,672 
Tax Rs m1,1903,0093,8273,1553,756 
Profit after tax Rs m4,7527,43011,0888,0399,250 
Gross profit margin %15.418.822.217.716.1 
Effective tax rate %20.028.824.328.233.1 
Net profit margin %7.29.712.18.89.4 
GLENMARK PHARMA BALANCE SHEET DATA
Current assets Rs m53,19959,04368,74669,88766,968 
Current liabilities Rs m37,11139,99327,02732,87940,211 
Net working cap to sales %24.324.945.440.727.1 
Current ratio x1.41.52.52.11.7 
Inventory Days Days7075858183 
Debtors Days Days138119969381 
Net fixed assets Rs m17,44521,41624,13228,89233,322 
Share capital Rs m271282282282282 
"Free" reserves Rs m23,08636,01444,64351,35355,770 
Net worth Rs m23,35736,29644,92551,63556,052 
Long term debt Rs m25,74424,87345,36341,41835,738 
Total assets Rs m87,429101,929117,639125,954132,888 
Interest coverage x4.16.87.64.94.4 
Debt to equity ratio x1.10.71.00.80.6 
Sales to assets ratio x0.80.80.80.70.7 
Return on assets %7.69.011.48.69.5 
Return on equity %20.320.524.715.616.5 
Return on capital %16.020.019.115.117.8 
Exports to sales %44.843.2000 
Imports to sales %7.17.4000 
Exports (fob) Rs m29,72033,044000 
Imports (cif) Rs m4,6805,672000 
Fx inflow Rs m31,29936,94556,15236,31762,998 
Fx outflow Rs m10,85661,0668,0849,72022,859 
Net fx Rs m20,443-24,12248,06826,59840,140 
GLENMARK PHARMA CASH FLOW
From Operations Rs m 4,817 3,449 6,574 16,481 13,242 
From Investments Rs m -5,400 -8,802 -7,124 -10,133 -6,990 
From Financial Activity Rs m 1,992 6,986 5,432 -4,685 -7,387 
Net Cashflow Rs m -311 934 1,992 1,770 -2,971 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 48.3%
Foreign collaborators 0.0%
Indian inst/Mut Fund 6.9%
FIIs 34.4%
ADR/GDR 0.0%
Free float 10.5%
Shareholders 56,727
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026
E-MAIL complianceofficer@glenmarkpharma.com WEB www.glenmarkpharma.com
TELEPHONE (022) 4018 9999 FAX (022) 4018 9986
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computer, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR Walker, Chandiok & Co.
CHM: Glenn Saldanha (MD) COMP SEC: Sanjay Kumar Chowdhary YEAR OF INC: 1977 BSE CODE: 532296 FV (Rs): 1 DIV YIELD (%): 0.4

Read: GLENMARK PHARMA 2018-19 Annual Report Analysis

More Pharmaceuticals Company Fact Sheets:   FULFORD INDIA  DR. REDDYS LAB  ALKEM LABORATORIES  JUBILANT PHARMOVA   ELDER PHARMA  

Compare GLENMARK PHARMA With:   FULFORD INDIA  DR. REDDYS LAB  ALKEM LABORATORIES  JUBILANT PHARMOVA   ELDER PHARMA  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  




Today's Market

Sensex Trades Marginally Higher, Dow Futures Up by 17 Points(12:30 pm)

Share markets in India are presently trading marginally higher. The BSE Sensex is trading up by 167 points, up 0.4% at 48,050 levels.

Views on news

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

More Views on News

Most Popular

My Recent Recommendation Will Profit from the Global Supply Chain Crisis (Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy (Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This... (Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

India: recovery stalled by vaccine games? (The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - SHASUN PHARMA COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS